Navigation Links
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
Date:12/11/2008

risk-sharing collaborations with companies in both India and China.

Tom Bumol, Ph.D., vice president of biotech discovery research, explained how the company's biotechnology strategy is transforming the Lilly pipeline. "We see more and more that biotech is a key to sustaining pharmaceutical innovation for the future, and Lilly has more than eight decades of experience with biologicals. Today, Lilly is the fifth largest biopharmaceutical company based on biotherapeutic sales, and we are making the necessary investments to strengthen our leadership position. Over the past decade, we have built a new integrated biotechnology infrastructure, from discovery through development, and including delivery devices and manufacturing."

Highlighting Lilly's growing biotech prowess, Dr. Paul remarked, "With the addition of the ImClone cancer antibodies, currently 40 percent of Lilly's clinical stage pipeline and 50 percent of Lilly's late-stage pipeline are comprised of biotechnology-based molecules. Through the ImClone acquisition, we have simultaneously accelerated our emergence as both a biotech and cancer powerhouse, with a pipeline that we believe will provide a continuous flow of high value medicines."

Key late-stage and select mid-stage compounds in each of the company's core therapeutic areas were reviewed by Drs. Paul and Bumol.

Select Pipeline Developments

-- Prasugrel - The company continues to invest heavily in the ongoing development of prasugrel. Prasugrel, which Lilly is developing with its partner Daiichi Sankyo, continues to be under review with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMEA) for treatment of acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI). Lilly remains in active dialogue with both regulatory agencies. In addition, prasugrel is also being studied in the TRILOGY trial in medically-ma
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 - Development of ... Using the VOLVOX Platform - To be Presented on ... -  Supramolecular Assembly of Antibody-drug Conjugates Using an anti-HER2 ... on Sunday, Apr 19, 1:00 PM EST ... program, today announced that the company,s novel computational platform ...
(Date:4/20/2015)... Whitehouse Laboratories is pleased and overly excited ... Food and Drug Administration (FDA) inspection and received no ... GMP compliance inspection, as based upon 21CFR Parts 210 ... 6th and was granted NAI (no action indicated) status. ... Good Manufacturing Practice (GMP) quality system required by the ...
(Date:4/17/2015)... , April 17, 2015 /PRNewswire/ - SQI Diagnostics ... and diagnostics company that develops and commercializes proprietary ... today announced that it has received approval from ... of 5,126,044 outstanding common share purchase warrants ("the ... connection with the Company,s May 2013 private placement ...
(Date:4/17/2015)... April 17, 2015 BellBrook Labs ... marketing support for the powerful Orthogonal Pooled Screening ... Genomics Center at the Lankenau Institute for Medical ... is to measurably improve successful drug discovery outcomes ... offering rare, drug-like libraries available nowhere else, coupled ...
Breaking Biology Technology:Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2
... of what may await them on Christmas morning. For me, December ... vying for a place at February's DEMO@15 show. While ... or so companies that will debut at the show, there are ... the conference gems we can unwrap now. , ,One such ...
... has received an undisclosed piece of its $8.5 million financing ... rare diseases, the company said. , ,The investment from a ... forming a new company, ZyStor, to buy its technology. , ... the Wisconsin investment that caught its attention. ...
... has almost finished teaching its first class of students in ... it has gained recognition and the opportunity to lead other ... grant on Tuesday of $495,000 from the U.S. Department of ... program. The funds are earmarked for an initiative to distribute ...
Cached Biology Technology:An early Christmas gift 2Gateway Technical College pilots IBM training program 2
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... April 2, 2015 Fingerprint Cards ... sensor FPC1025 from the distributor World Peace Industrial Group ... Q2 2015 although the major part of the shipments ... be used by smartphone manufacturers in China ... included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... born every day in the brain,s hippocampus, but what controls ... 1 issue of Science , neuroscientists at the Johns ... of new cells, which depends on brain activity, also depends ... in the cell,s genetic material. "How is it ...
... The evolutionary history of diatoms -- abundant oceanic plankton ... air each year -- needs to be rewritten, according to ... sudden rise in species numbers, diatoms abruptly declined about 33 ... cooling. , The study is published in the Jan. 8 ...
... gas, believed to be among the cleanest forms of ... in home appliances such as stove tops and water ... issue (Volume 25, Number 10) of Environmental Engineering ... Ann Liebert, Inc. The paper is available free online ...
Cached Biology News:Growth of new brain cells requires 'epigenetic' switch 2Decline of carbon-dioxide-gobbling plankton coincided with ancient global cooling 2
One-step, microplate or cuvet, colorimetric 530nm, detection limit 0.16mg/dL in serum or plasma. Procedure: 10 min....
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
...
MSE ANTI CAN. CD3:FITC/RAT ANTI CD4:RPE...
Biology Products: